Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 4/20 | 0.33 |
| ▸ | JUN | P05412 | 3/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.33 |
| ▸ | RELA | Q04206 | 3/20 | 0.33 |
| ▸ | STK17B | O94768 | 1/20 | 0.33 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | ATF1 | P18846 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28328264 | 0.82 | PIN1 (0.36) | NFKB1STK17BSTK17ADGAT1ALDH1A1 | |
| SCHEMBL31582761 | 0.75 | ALDH1A1 (0.34) | ALDH1A1POLB | |
| SCHEMBL4579208 | 0.73 | NOS3 (0.36) | NFKB1JUNNFKB2RELAALDH1A1 | |
| SCHEMBL30238970 | 0.73 | NOS3 (0.36) | NFKB1JUNNFKB2RELAALDH1A1 | |
| SCHEMBL30135511 | 0.72 | JUN (0.35) | NFKB1JUNNFKB2RELAALDH1A1 | |
| SCHEMBL1404490 | 0.70 | KDM4E (0.37) | NFKB1JUNNFKB2RELAALDH1A1 | |
| SCHEMBL27145902 | 0.70 | LMNA (0.35) | NFKB1JUNNFKB2RELALMNA | |
| Formic Acid SCHEMBL29024515 | 0.69 | JUN (0.33) | NFKB1JUNNFKB2RELALMNA | |
| SCHEMBL17589035 | 0.69 | PDCD1LG2 (0.38) | NFKB1JUNNFKB2RELASTK17B | |
| SCHEMBL16580713 | 0.69 | PDXK (0.48) | NFKB1JUNNFKB2RELALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110452179-A | A kind of synthetic method of 2- chloro-4-methoxy -5- cyanopyrimidine | NANJING PURUIDA PHARMACEUTICAL TECH CO LTD | 2019-11-15 | — | — | CN | disclosed |
| US-7825128-B2 | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | BAYER SCHERING PHARMA AG (DE) | 2010-11-02 | — | — | US | disclosed |
| US-20070232632-A1 | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232632-A1 | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | TYMS, DPYD, DHFR | NFKB1 2954/4885JUN 4140/4885NFKB2 3838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.